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regimens for hematopoietic stem cell transplantation (HSCT).
Methods: Analysis of all patients who received an allogeneic,
matched-sibling (6/6) HSCT for myeloid malignancies enrolled in
4 different transplant studies between 4/97 and 12/04. These
studies included 3 preparative regimens: (1) IV Busulfan, 130
mg/m2  4 days and Fludarabine, 40 mg/m2  4 days (IVBuFlu);
(2) IV Busulfan, 0.8 mg/kg q6h  4 days and Cyclophosphamide,
60 mg/kg  2 days (IVBuCy), and (3) Fludarabine, 30 mg/m2  4
days and Melphalan, 180 mg/m2 (FM). All patients received the
same GVHD prophylaxis with tacrolimus and minidose metho-
trexate. Results: A total of 176 patients (IVBuFlu 89, IVBuCy
60, and FM  27) were analyzed, and patients’ characteristics are
summarized in Table 1. The median age was signiﬁcantly higher in
the FM group compared to the IVBuFlu and IVBuCy groups.
IVBuFlu had a signiﬁcantly higher proportion of peripheral blood
stem cell transplants (PBSCT) compared with IVBuCy, and more
patients with mixed chimerism on day 30 post transplant compared
with both IVBuCy and FM. The rate of Grade 2-4 acute GVHD
was lowest in the IVBuFlu group (18%), compared with IVBuCy
(34%, P  .01) and FM (26%, P  .2). IVBuFlu continued to have
a signiﬁcantly lower rate of Grade 2-4 acute GVHD among pa-
tients with donor chimerism. Grade 3-4 acute GVHD also favored
the IVBuFlu group (3%) in comparison with IVBuCy (12%, P 
.03) and FM (11%, P .05). The incidence of chronic GVHD was
similar in all regimens. NRM at 1 year was 9% with IVBuFlu, 17%
with IVBuCy (P .2) and 33% with FM (P .002). Conclusions:
The incidence of acute GVHD and NRM differs among myeloa-
blative regimens. These differences are only partially explained by
regimen intensity (Table1).
Table 1. Patients Characteristics
FM
(n  27)
IVBuCy
(n  60)
IVBuFlu
(n  89)
IV BuFlu
vs FM
IVBuFlu vs
IVBuCy
Median F/U (mo) 63 (38-81) 62 (19-75) 22 (6-50)
Median Age 54 40 47 P < .001 P  .06
MDS/AML 16 (59%) 36 (60%) 89 (100%)
CML 11 (41%) 24 (40%) 0
PBSC 24 (89%) 41 (68%) 76 (85%) P  .5 P  .01
Donor/Mixed
chim 81%/4% 90%/3% 62%/30% P  .05 P < .001
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THE COMPLEX CARE CHALLENGE OF TRANSPLANT PATIENTS AND
FAMILIES: HOW TO EFFECTIVELY PROMOTE CARE ACROSS THE CON-
TINUUM THROUGH ROLE DEVELOPMENT IN THE PROGRAM
Schulte, K.A., Hubner, M., Binari, E., Gaumer, C. Dana-Farber/
Brigham & Women’s Cancer Center, Boston, MA.
Topic: Ambulatory Care Coordination is a synergistic model of
care that provides assistance to transplant (BMT) patients and their
families who are high risk from a clinical and/or ﬁnancial perspec-
tive; eg, second transplant, psychosocial needs, limited ﬁnancial
and or socioeconomic resources, or limited insurance coverage.
Abstract: A multidiscipinary team inclusive of nursing leadership,
administrative leadership, research/program nurses, social workers,
and care coordination nurses had the oppurtunity to assist with the
development and implementation of a new role. This nurse’s role
would be to assist in providing a seamless continuum of patient
care between the ambulatory and inpatient setting, as a well as to
build a bridge to community and home care services. Purpose:
The purpose of this project was to design, develop, and implement
a new nursing role, the Ambulatory BMT RN Care Coordinator.
Our goal was to have this nursing role actively participate in the
pretransplant process. A large focus of the role is to identify
potential discharge issues prior to patient admission by developing
preliminary discharge plans for identiﬁed patients. Interventions:
A multidisciplinary task force met to create a job description and
role. This role was developed from discussion/feedback from in-
patient/oupatient members of nursing staff, social work, ﬁnancial
counselors, and administration. Interpretation:Monthly meetings
have been coordinated between the inpatient and outpatient
groups to evaluate the communication and process on an ongoing
basis. Monthly meetings between the Ambulatory Nurse Leader,
the program/research transplant nurses, the RN Program Manager
for Care Coordination, and the Ambulatory BMT RN Care Co-
ordinator occur in order to continually evaluate the program for its
effectiveness, ease of communication, and its ability to provide
continuous care coordination across both the ambulatory and in-
patient settings. Since inception of this program, 14 months, 225
patients have been identiﬁed and managed by the Ambulatory
BMT RN Care Coordinator. As a result of being exposed to
multiple aspects of the transplant process, this role has served to
identify process and system issues and trends in the industry, eg,
limited pharmacy beneﬁts. Discussion: The ﬁnancial, psychoso-
cial, and clinical needs of this patient population are highly com-
plex and require clear pathways of communication to achieve the
best possible patient outcomes.
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SUCCESSFUL MOBILISATION, HARVEST, AND TRANSPLANT OF STEM
CELLS FOLLOWING AMD3100 IN 3 PAEDIATRIC PATIENTS. THE AUS-
TRALIAN EXPERIENCE
Stephen, K.1, Montgomery, K.1, Bateman, C.1, Calandra, G.2,
Shaw, P.J.1 1. The Children’s Hospital at Westmead, Sydney, NSW,
Australia; 2. AnorMED, Langley, BC, Canada.
We report the successful mobilisation and subsequent transplant
of three patients, using granulocyte cell stimulating factor (GCSF)
and AMD3100, who had failed previous mobilisation attempts.
AMD3100 is a potent and selective antagonist of the CXCR4
chemokine receptor, and blocks binding of its cognate ligand,
encouraging the release of haematopoietic stem cells into the
peripheral circulation. AMD3100 was obtained on a compassionate
basis from AnorMed and given as per protocol, with a pre phase of
10mcg/kg GCSF for 4 days and AMD3100 240mcg/kg given
subcutaneously on day 5, 10-11 hours prior to apheresis and then
given daily until the required number of cells were collected. The
patients diagnoses were Ewings sarcoma, ALL, and Medulloblas-
toma. All were male patients aged between 10-17 years: the 10-
year-old being the youngest patient at the time of administration,
to have received AMD 3100. Each patient had a history of failed
mobilization following a range of regimens and between 1 to 4
attempts at mobilization prior to the commencement of
AMD3100. No side effects of treatment with AMD3100 were
noted. All were successfully collected with adequate PBSCs to
enable reinfusion after either myeloablative chemotherapy or se-
quential tandem high dose therapy (for medulloblastoma). The
Ewing’s sarcoma patient was conditioned with Busulfan/melphalan
and recovered neutrophils of 0.5 109/l after 14 days; he remained
platelet dependent as he progressed soon after BMT. The ALL
patient received total body irradiation 1320 cGy and melphalan
and recovered to neutrophils 	 0.5  109/l after 23 days and
platelets 	 50  109/l after 29 days. The patient with medullo-
blastoma received 4 courses of high dose multiagent therapy with
stem cell rescue and showed prompt haematological recovery after
each course. These three cases illustrate that AMD3100, in com-
bination with GCSF, can achieve successful mobilization and stem
cell collection in previously poorly mobilizing patients. This al-
lowed subsequent delivery of myeloablative chemotherapy fol-
lowed by autologous PBSC infusion and sustained engraftment in
these patients.
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INCREASING THE SAFETY OF PATIENT-ADMINISTERED OUTPATIENT
CONDITIONING THERAPY WITH ORAL BUSULFAN
Wickline, M.M. 1Seattle Cancer Care Alliance, Seattle, WA.
Patient-administered chemotherapy in the home is without the
controls and safeguards of nurse-administered chemotherapy in
the clinical setting. Oral Busulfan is commonly used as condition-
ing chemotherapy for patients undergoing Hematopoietic Stem
Cell transplantation (HSCT). Because the treatment schedule is
every 6 hours, and patients are usually well enough to remain
outpatient, patients at the Seattle Cancer Care Alliance self-ad-
minister Busulfan at home. Historically, this practice made it dif-
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